- The shares of TFFP have slumped, most likely as a result of disappointment over an absence of a deal with one of the top mRNA vaccine producers.
- However, besides a host of programs developed alone or with partners, the TFF platform remains very relevant for both vaccines as well as therapeutics combating Covid.
- The company has a host of partners in the Covid space and the company is likely to reward patient investors.
- Learn More »